(Q38206821)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

title

Dendritic cell-based vaccines: clinical applications in breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

Michelino De Laurentiis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Michele Santangelo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Giuseppe Curigliano

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

10

Aron Goldhirsch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

2

Carmen Criscitiello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

author name string

Lucia Gelao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Angela Esposito

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Luca Fumagalli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Marzia Adelia Locatelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Ida Minchella

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Sabino De Placido

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

publication date

1 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

page(s)

349-360

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24762078%20AND%20SRC:MED&resulttype=core&format=json

Immune responses in cancer

15 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

The mechanisms of cancer immunoescape and development of overcoming strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Co-culture of apoptotic breast cancer cells with immature dendritic cells: a novel approach for DC-based vaccination in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Breast cancer vaccines: promise for the future or pipe dream?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunotherapy and the concept of a clinical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Human dendritic cell subsets in vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunotherapeutics for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunity and autoimmunity: revising the concepts of response to breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Enhancement of dendritic cells as vaccines for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Tolerogenic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Dendritic cells in the cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Dendritic cells are dysfunctional in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Dendritic cells as vectors for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunotherapy with dendritic cells for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunotherapy for advanced melanoma: fulfilling the promise

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

A new age for vaccine therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Prophylactic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Trial watch: Dendritic cell-based interventions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Optimization of leukocyte collection and monocyte isolation for dendritic cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Improvement of cancer immunotherapy by combining molecular targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Tumor-associated antigens in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169

Immunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.169